growth-hormone-receptor

Growth Hormone Receptor (GHR)

The transmembrane receptor for pituitary growth hormone (GH) — the molecular entry point for the GH–IGF-1 axis, one of the most studied longevity pathways in biology. GHR loss-of-function in both mice (GHR-KO) and humans (laron-syndrome) is associated with markedly extended healthspan and reduced cancer and diabetes incidence, constituting the clearest genetic evidence in any mammalian species that attenuation of this axis extends healthy longevity ¹².

Identity

• UniProt: P10912 (GHR_HUMAN)
• NCBI Gene: 2690
• HGNC: 4263
• Ensembl: ENSG00000112964
• Mouse ortholog: Ghr (one-to-one; highly conserved)
• GenAge entry: 1 (first entry in HAGR/GenAge database)
• Length: 638 amino acids (canonical isoform)
• Family: Cytokine receptor superfamily, Class I (hematopoietin receptor superfamily)

Structure and signaling mechanism

GHR is a single-pass Type I transmembrane protein consisting of:

• Extracellular domain — two fibronectin type-III (FNIII) subdomains flanking the WSXWS motif; contains the hormone-binding site
• Single transmembrane helix
• Intracellular domain — Box 1 and Box 2 motifs required for constitutive JAK2 association; no intrinsic kinase activity

A key structural feature: GHR exists as a pre-formed homodimer at the cell surface prior to GH binding. GH engagement induces a conformational rearrangement within the dimer — not new dimerization — that repositions the two JAK2 molecules (one bound per GHR monomer), enabling transphosphorylation and kinase activation. This distinguishes GHR signaling from many receptor tyrosine kinases where ligand-induced dimerization is the activating step. needs-citation — the pre-formed dimer model was established by structural work after Leung 1987 (cloning paper); cite Brown et al. 2005 PNAS and/or de Vos et al. 1992 Science for the dimerization mechanism.

Downstream signaling branches

Upon GH binding and JAK2 activation:

1. JAK2–STAT5 (primary) — STAT5a/b phosphorylation; primary transcriptional driver of hepatic IGF1 gene expression needs-citation — Leung 1987 is a cloning paper and does not characterize JAK2-STAT5 signaling; cite Argetsinger et al. 1993 Cell (JAK2 discovery) and/or Darnell et al. 1994 Science (STATs) for signaling mechanism
2. JAK2–STAT3 — overlapping with cytokine signaling; contributes to immune and metabolic regulation
3. JAK2–ERK (RAS–MAPK) — growth, proliferation, metabolic effects via the ras-mapk pathway
4. JAK2–PI3K–AKT — insulin-sensitizing and metabolic effects via the pi3k-akt-pathway; substantial crosstalk with insulin receptor signaling at IRS-1/IRS-2 level

The dominant aging-relevant output is hepatic IGF-1 production: liver-derived IGF-1 constitutes the primary endocrine signal connecting pituitary GH to peripheral growth and metabolic effects ³. The commonly cited ~75% figure for the hepatic contribution to circulating IGF-1 is not sourced to a primary citation on this page. needs-citation

Splice variants and soluble form

• Full-length GHR (638 aa) — canonical signaling isoform
• Truncated GHRtr — exon-skipped variant lacking portions of the intracellular domain; functions as a decoy receptor; modulates signal amplitude
• Growth Hormone Binding Protein (GHBP) — the shed extracellular domain of GHR, generated by ADAM-mediated ectodomain shedding; circulates in plasma as a GH reservoir/buffer; serum GHBP levels serve as a proxy for hepatic GHR expression needs-replication in aged cohorts

Tissue expression

Primary sites of GHR expression and IGF-1 production:

• Liver — dominant source of circulating IGF-1; primary metabolic and growth signal
• Skeletal muscle — autocrine/paracrine GH effects on protein synthesis; relevant to sarcopenia
• Adipose tissue — GHR drives lipolysis; loss of GH signaling shifts toward adiposity but paradoxically improves insulin sensitivity
• Bone — GHR mediates both direct GH effects and IGF-1 endocrine effects on osteoblasts
• Immune cells — GH has immunomodulatory roles; thymic GHR implicated in age-related thymic involution
• Brain — GHR expressed in hypothalamus, hippocampus; GH has direct CNS effects on cognition and neuroprotection

Aging context — the longevity paradox

GHR sits at a major intersection of aging biology: robust evidence from multiple species and human genetics demonstrates that attenuation of GH–GHR–IGF-1 signaling extends lifespan and delays several hallmarks of aging. This directly conflicts with the GH-replacement narrative (GH declines with age = somatopause → treat with GH to reverse aging phenotypes), which the longevity evidence does not support.

Model organism evidence

Ames dwarf mice (Prop1^df mutation — GH/PRL/TSH pituitary deficiency): live substantially longer than wild-type littermates, with extended healthspan, reduced cancer, improved insulin sensitivity, and delayed age-related pathology ⁴. The specific percentage range (often cited as 30–50% in secondary literature) could not be confirmed from the 1-page Nature letter (no abstract; full text closed-access). needs-replication — verify exact lifespan extension percentage against full text.

Snell dwarf mice (Pit1 mutation, similar pituitary deficiency): similar longevity extension; independent genetic validation.

GHR-KO mice (Laron mouse equivalent — global GHR deletion):

• Severely reduced circulating IGF-1 and IGFBP-3; fasting insulin and glucose reduced; body weight severely decreased ¹
• Lifespan significantly extended vs WT controls (exact percentage not stated in Coschigano 2003 abstract; closed-access; often cited in secondary literature as ~35–40%) needs-replication — verify exact percentage against full text
• Deletion required complete loss: mice expressing a GH antagonist (without GHR deletion) showed no lifespan benefit and weights approached controls over time — full receptor elimination was necessary ¹
• Improved insulin sensitivity despite adiposity; no age-related diabetes

GH-overexpressing transgenic mice: dramatically shortened lifespan with early-onset kidney pathology (glomerulosclerosis/glomerulonephritis), accelerated cognitive aging, shortened reproductive lifespan, and multiple symptoms of accelerated aging — the mirror image of the longevity evidence ⁵. The specific percentage reduction (sometimes cited as 50–60% in secondary literature) could not be confirmed from the available abstract; full text is closed-access. needs-replication

Dimension	Status	Notes
Pathway conserved in humans?	yes	GHR cloning confirmed identical signaling architecture human/rabbit/mouse 6
Phenotype conserved in humans?	yes	Laron syndrome = human GHR-KO equivalent; reduced cancer + diabetes confirmed 2
Replicated in humans?	partial	Laron cohort is small (~250 known cases worldwide); no RCT; observational; the full lifespan extension seen in mice not established in human LoF cohort

Human genetic evidence — Laron syndrome

Laron syndrome (OMIM 262500) is caused by loss-of-function mutations in GHR, resulting in complete GH insensitivity. First described by Zvi Laron in 1966; the molecular basis (GHR LoF) established after the Leung 1987 cloning.

The Ecuadorian Laron cohort studied by Guevara-Aguirre et al. (n=99 GHRD subjects monitored since 1988 vs 1,606 unaffected first-to-fourth-degree relatives) showed ²:

• Near-absent cancer incidence: only 1 cancer case among 99 GHRD subjects (papillary serous epithelial ovarian tumor); vs 17% cancer prevalence in relatives; cancer accounted for 0% of GHRD deaths vs 20% of relative deaths (p=0.003). The paper does not state a “5-fold” fold-reduction; the actual contrast is closer to complete absence vs 17–20%.
• No diabetes in the affected cohort (0/90 living subjects; 95% CI 0–4%; p=0.02) vs diabetes accounting for ~5% of relative deaths and ~6% of all diseases in relatives
• Reduced IGF-1 (≤20 ng/mL in all GHRD subjects vs mean 144 ng/mL in relatives), reduced IGF-II, reduced fasting insulin (~1/3 of relatives); HOMA-IR 0.34 vs 0.96 (p<0.05)
• No statistically significant lifespan extension (cohort size limits power; accidental/non-age-related deaths account for 21 of 30 deaths in GHRD subjects over 10 years of age)

The absence of a demonstrated lifespan extension in humans with Laron syndrome (despite the robust disease-protection signal) may reflect: small sample size, high accidental-death rate, and the distinction between healthspan vs lifespan in humans with severe dwarfism ³.

d3-GHR polymorphism — a common deletion of exon 3 producing a shorter GHR isoform with altered signaling; associated with ~10-year lifespan extension in some population-level analyses (GenAge entry 1), though replication is inconsistent. contradictory-evidence

The somatopause paradox

GH secretion declines with age after peak in adolescence (somatopause), with parallel decline in circulating IGF-1. The specific rate (~14% per decade is a commonly cited figure) is not sourced to a citation on this page; needs-citation. This decline is associated with:

• Sarcopenic muscle loss, reduced bone density, increased visceral adiposity
• Reduced exercise capacity and cognitive slowing

The longevity literature suggests these somatopause-associated changes may be a feature, not a bug: reduced GH–IGF-1 throughput may slow the rate of cellular damage accumulation, analogous to the CR-mTOR-axis logic. However, the clinical presentation of somatopause (frailty, body composition changes) creates pressure toward GH replacement — a tension not yet resolved by RCT evidence ³⁷.

The paradox is summarized in the igf-1-biomarker page, which documents the U-shaped relationship between circulating IGF-1 and all-cause mortality in human cohorts.

MR-causal evidence: Extensive Mendelian randomization evidence from GHR/IGF-1 axis genetics supports causal roles in longevity, cancer, and metabolic disease. The Laron syndrome itself constitutes a natural MR experiment with large effect sizes ².

Pharmacology

Pegvisomant (Somavert) — FDA-approved 2003

Pegvisomant is a PEGylated GHR antagonist engineered from a B2036 GHR-competitive mutant that binds GHR but blocks productive GH-induced conformational rearrangement. FDA-approved for acromegaly (excess GH/IGF-1 from pituitary adenomas). Reduces serum IGF-1 by 60–80% at clinical doses.

Aging-context tier-1 rationale: Pegvisomant achieves GHR-level pharmacological blockade — the same intervention logic as GHR-KO in mice — and is FDA-approved for a GH-excess endocrine disorder. No aging-indication RCT has been conducted. Aging research interest is active but all evidence is mechanistic/translational ³. The drug’s efficacy makes the target highly tractable; the clinical trial gap makes the translation speculative.

Aging-context tier: 1 (FDA-approved drug targeting GHR exists; acromegaly indication; not aging-validated).

MK-677 (ibutamoren) — opposite direction

mk-677 is a ghrelin mimetic / growth hormone secretagogue that acts on ghsr to stimulate pituitary GH release, thereby increasing GHR engagement and IGF-1 production. From the longevity-biology perspective, MK-677 pushes the axis in the opposite direction from what GHR-KO data suggest is beneficial. See mk-677 for full evidence.

BPC-157 — GHR modulation claim (R36)

bpc-157 has been claimed to modulate GHR signaling; this claim is the forward-queue source for this page. The mechanistic basis is not well-established in peer-reviewed literature; the claim should be verified against primary sources before citation. needs-replication

Pathway membership

• jak-stat-pathway — GHR → JAK2 → STAT5a/b → IGF1 transcription (primary axis)
• insulin-igf1 — GHR is the upstream activator of hepatic IGF-1 that feeds into the canonical insulin-igf1 axis; substantial IRS-1/2 crosstalk
• pi3k-akt-pathway — downstream of JAK2; overlaps with insulin PI3K-AKT; relevant to deregulated-nutrient-sensing
• ras-mapk — mitogenic arm downstream of JAK2

Note: a dedicated [[gh-jak-stat-pathway]] page does not yet exist; GH–JAK2–STAT5 signaling is currently described under jak-stat-pathway. stub — recommend seeding gh-jak-stat-pathway.md to capture GH-specific biology distinct from cytokine JAK-STAT.

Key interactors

• growth-hormone — cognate ligand; pre-formed GHR dimer undergoes conformational change upon GH engagement
• igf-1 — primary downstream output of hepatic GHR signaling; circulating IGF-1 mediates most peripheral GHR effects
• igf1r — IGF-1 receptor; mediates most downstream effects of GHR-stimulated IGF-1 production
• irs-1 / IRS-2 — signaling intermediates bridging JAK2 and PI3K; node of insulin/IGF-1 axis convergence
• ghsr — GH secretagogue receptor (upstream); controls pituitary GH release that activates GHR

Limitations and gaps

• Human longevity data are observational and from small LoF cohorts. Laron syndrome is rare (~250 cases worldwide); the Ecuadorian cohort is n=99 monitored GHRD subjects. Statistical power to detect lifespan differences against the noisy background of accidental/non-age-related deaths (21 of 30 deaths in Guevara-Aguirre 2011 cohort over age 10 were non-age-related) is limited ². needs-replication
• Tissue-specific GHR roles are incompletely mapped. Liver-specific GHR-KO (LiGHRKO) produces a different (milder, more metabolic) phenotype than global GHR-KO, but aging phenotype data are limited. no-mechanism
• Pegvisomant aging-indication gap. No human RCT has tested GHR antagonism for aging or longevity endpoints. The mechanistic case is strong; the translational gap is large. needs-human-replication
• somatopause intervention trial gap. It remains unknown whether partial GHR downregulation (vs full genetic knockout) in aged humans would produce the same protective effects seen in Laron syndrome. needs-human-replication
• GTEx aging correlation not yet queried. The gtex-aging-correlation: field is unpopulated. not-queried
• d3-GHR polymorphism replication inconsistent. The 10-year lifespan extension claim from the exon-3 deletion polymorphism is not consistently replicated across cohorts. contradictory-evidence

Footnotes

Footnotes

1. doi:10.1210/en.2003-0374 · Coschigano KT et al. · Endocrinology 2003 · 144:3799–3810 · in-vivo (GHR-KO mouse, C57BL/6J background, global deletion) · full GHR deletion → significantly extended lifespan + severely reduced body weight, fasting insulin, IGF-1, and IGFBP-3; GH antagonist expression (without GHR deletion) did not extend lifespan and weights approached controls over time, showing complete receptor elimination was required; exact lifespan extension percentage not stated in abstract (closed-access) · PMID 12933651 ↩ ↩² ↩³

2. doi:10.1126/scitranslmed.3001845 · Guevara-Aguirre J et al. · Science Translational Medicine 2011 · observational (n=99 GHRD subjects monitored since 1988 vs 1,606 unaffected first-to-fourth-degree relatives; serum analysis subgroup n=16 GHRD vs 13 relatives) · 1 cancer case in GHRD vs 17% cancer prevalence in relatives; cancer = 0% of GHRD deaths vs 20% of relative deaths (p=0.003); 0 diabetes cases in 90 living GHRD subjects (95% CI 0–4%; p=0.02) vs ~5–6% in relatives; IGF-I ≤20 ng/mL in all GHRD vs mean 144 ng/mL relatives; HOMA-IR 0.34 vs 0.96 (p<0.05); cited 731 times · PMC3357623 (OA) ↩ ↩² ↩³ ↩⁴ ↩⁵

3. doi:10.1210/er.2018-00216 · Aguiar-Oliveira MH, Bartke A · Endocrine Reviews 2019 · 40:575–609 · review · comprehensive synthesis of GH deficiency → longevity evidence across mice, rats, and humans; IGHD Brazilian cohort (Itabaianinha, n=105 GHRHR-mutant) achieves healthspan extension and some centenarians (one case ≥103 y); discusses Laron syndrome longevity in Israeli (n=64) and Ecuadorian (n=99) cohorts; archive PMC6416709 ↩ ↩² ↩³ ↩⁴

4. doi:10.1038/384033a0 · Brown-Borg HM, Borg KE, Meliska CJ, Bartke A · Nature 1996 · 384:33 · in-vivo (Ames dwarf mice, Prop1^df) · foundational demonstration that GH/PRL/TSH-deficient dwarf mice live substantially longer than WT littermates; landmark paper establishing the GH–longevity connection; cited >1060 times · PMID 8900272 · note: 1-page letter; no abstract in PubMed; full text closed-access; exact lifespan extension percentage could not be verified from available sources ↩

5. doi:10.1159/000073704 · Bartke A · Neuroendocrinology 2003 · 78(4):210–216 · review · GH-transgenic mice (excess GH signaling) have drastically shortened lifespan with early-onset kidney pathology (glomerulosclerosis/glomerulonephritis), accelerated cognitive aging, and symptoms of accelerated aging; supports bidirectional causal role of GH axis in lifespan; specific percentage reduction not stated in abstract (closed-access) · PMID 14583653 ↩

6. doi:10.1038/330537a0 · Leung DW, Spencer SA, Cachianes G et al. · Nature 1987 · 330:537–543 · n=N/A (biochemical/molecular cloning) · purified GHR from rabbit liver; serum GH-binding protein from rabbit serum shares amino-terminal sequence with the receptor extracellular domain; also obtained cDNA clones for human GHR; established GHR as a new class of transmembrane receptors (cytokine receptor superfamily). Note: this paper covers cloning only — it does not characterize JAK-STAT signaling or dimerization state · PMID 2825030 ↩

7. doi:10.14310/horm.2002.1196 · Laron Z · Hormones 2008 · 7:24–27 · review · IGF-1 deficiency and GHR disruption extend lifespan across species; Laron syndrome patients protected from cancer; elevated GH/IGF-1 accelerates mortality · PMID 18359741 · ⚠️ DOI-mapping error: a local lookup returned a different Hormones paper (Psyrogiannis et al., iron overload/DM2) at this DOI — claims sourced to this footnote are unverifiable from the local copy; PMID 18359741 should be confirmed independently ↩